Alnylam Pharmaceuticals | ALNY - Zinsaufwendungen Für Schuld

Aktienkurs
297.90
Täglich Wechseln
-4.21 -1.39%
Monatlich
-5.75%
Jährlich
13.17%
Q2 Prognose
299.00




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Arrowhead Research USD 22.5M 811K 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 281M 8M 2025-09
PTC Therapeutics USD 50.58M 2.59B 2025-12
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Takeda JPY 123.63B 40.49B 2025-12
Tectonic Therapeutic USD 12K 276.99M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 311K 2025-12